

BRAF^{V600E} Efficient Transformation and Induction of Microsatellite Instability Versus KRAS^{G12V} Induction of Senescence Markers in Human Colon Cancer Cells^{1,2}

Eftychia Oikonomou^{*,3}, Eleni Makrodouli^{*,3}, Maria Evagelidou[†], Tobias Joyce^{*}, Lesley Probert[†] and Alexander Pintzas^{*}

*Laboratory of Signal Mediated Gene Expression, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece; [†]Laboratory of Molecular Genetics, Hellenic Pasteur Institute, Athens, Greece

Abstract

In colorectal cancer, *BRAF* and *KRAS* oncogenes are mutated in about 15% and 35% respectively at approximately the same stage of the adenoma-carcinoma sequence. Since these two mutations rarely coexist, further analysis to dissect their function of transformation in colon cancer is required. Caco-2 human colon adenocarcinoma cells were stably transfected with *BRAF*^{V600E} (Caco-BR cells) or *KRAS*^{G12V} (Caco-K cells) oncogenes. *BRAF*^{V600E} is more efficient in transforming Caco-2 cells and altering their morphology. The dominant nature of *BRAF*^{V600E} is evident by its ability to render Caco-2 cells tumorigenic *in vivo* all be it *through* selective extracellular signal-related kinase (ERK) 2 phosphorylation and high levels of cyclin D1. As a consequence, the cell cycle distribution of parental cells is altered and microsatellite instability is introduced. Attenuated ERK activation observed *correlated* with KSR downregulation by *BRAF*^{V600E} without further implications to signaling. Highly *activated* ERK in case of *KRAS*^{G12V} (Caco-K cells) *leads* to mild transformation *causing* Caco-K cells to express premature senescence-related markers and *acquire* growth factor-dependent viability. Interestingly, *BRAF*^{WT} *gets* equally activated by upstream *KRAS* mutations present in colon adenocarcinoma cells such as DLD-1 and SW620. Taken together, these results suggest that the two oncogenes have different transforming capability in colon cancer, although they both use the mitogen-activated protein (MAP) kinase pathway to carry out their effect. In general, *BRAF*^{V600E} presents greater potential in mediating tumorigenic effect as compared to *KRAS*^{G12V} both *in vivo* and *in vitro*. These findings may have implications in personalised diagnosis and targeted therapeutics.

Neoplasia (2009) 11, 1116–1131

Introduction

Colorectal cancer (CRC) can be either hereditary or sporadic characterized by deregulated signal pathways and cellular programs through gain and/or loss of function mutations that accumulate in a stepwise manner. Among the most hurtful of all genetic abnormalities that appear in CRC development are *KRAS* and its downstream effector *BRAF* because they result to abnormal extracellular signal-related kinase (ERK) signaling. Approximately 13% and 35% of CRC contain activating point mutations in the *BRAF* and *KRAS* genes, respectively [1–4]. Mutant RAS proteins end up losing their initially high GTPase enzymatic activity [5], with mutations in codon 12 by far the most frequent compared with codon 13 [1,6]. Recent evidence suggests that different mutations in *KRAS* have different biological consequences

Address all correspondence to: Alexander Pintzas, PhD, Laboratory of Signal Mediated Gene Expression, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Vasileos Constantinou Ave 48, 11635, Athens, Greece.

E-mail: apint@ie.gr

¹This work is supported by the European Union grants LSHC-CT-2006-037278 “ONCODEATH,” MTKD-CT-2004-509836 “MACROGENEX,” MRTN-CT-2004-504228 “TAF-Chromatin,” and GSRT grant 03 ED562 to A.P.

²This article refers to supplementary materials, which are designated by Tables W1 and W2 and Figures W1 and W2 and are available online at www.neoplasia.com.

³These authors equally contributed to this work.

Received 22 March 2009; Revised 24 July 2009; Accepted 28 July 2009

Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/\$25.00
DOI 10.1593/neo.09514

in vivo. In addition, although G12D seems to be more frequent compared with G12V in colon cancer, KRAS^{G12V} has been associated with more aggressive colorectal carcinomas and greater mortality than other codon 12 or 13 mutations [7–9]. Downstream the RAS-RAF–mitogen-activated protein kinase (MAPK) pathway is BRAF, which is activated through binding to RAS-GTP.

Activated RAF kinases phosphorylate MAPK/ERK kinase (MEK), which in turn phosphorylate and activates ERK. *BRAF* has been identified as an oncogene in human cancer especially in malignant melanoma and colon carcinoma. Analysis of mutations in human colorectal tumors showed that more than 80% of the BRAF mutations were BRAF^{V600E} (constitutive activation of BRAF kinase) and that this mutation greatly increased ERK and nuclear factor κ B signaling when transformed in NIH3T3 cells [10]. It is believed that activated BRAF and KRAS have a causal role in the development of cancer and cell transformation [5,11,12]. Various RAS inhibitors have been examined for their ability to block signaling in these constitutive active mutants, and isoprenylation inhibitors have been proven to be ineffective in clinical trials [13]. Therefore, greater focus has been placed on the downstream RAF molecules.

BRAF and KRAS have the potential to regulate similar as well as different pathways. Similarly, although phosphatidylinositol 3-kinase (PI3K) is activated by Ras in fibroblasts, Ras is not an activator of the PI3K/Akt pathway in T lymphocytes [14].

Mutational activation of oncogenes such as *KRAS* and *BRAF* results to constitutive ERK signaling, which can lead to cell cycle changes that have a profound influence on the G₁/S transition by regulating the expression of a number of cell cycle proteins such as cyclins D and E and inhibitors such as p21^{Cip1} and p27^{Kip} [15,16]. Induction of senescence or tumorigenesis depends on the expression of cell cycle regulatory proteins (p21^{Cip1}, p16^{INK4a}, p14^{ARF}, p15^{INK4b}, p19^{ARF}, and p53). Similarly, cyclin D1 is equally important for the development and progression of several cancers, including colon cancer, and it has been found that it is significantly upregulated and related to a more aggressive tumor phenotype and poor prognosis [17,18]. Cyclin E, often found overexpressed in cancer, can efficiently induce the phosphorylation of Rb, thus causing its functional inactivation, which contributes to tumorigenesis. Similarly, high levels of the p21^{Cip1} inhibitor have been associated with RAS signaling and with the clinical progression of malignant melanoma [19]. All these incidents have in common a mutated *BRAF* or *KRAS* gene and result to high cell proliferation through increased ERK signaling. Nevertheless, hyperactivation of the ERK pathway can also lead to the opposite situation, cell cycle arrest, and p53-dependent or -independent senescence [20–22]. More specifically, sustained BRAF^{V600E} expression in human melanocytes induces cell cycle arrest, along with induction of both p16^{INK4a} and senescence-associated β -galactosidase (SA- β -Gal) activity [23]. By contrast, the expression of oncogenic RAS in primary human or rodent cells results in premature senescence and allows proliferation to continue unabated in the presence of oncogenic stimuli [24].

Oncogenes have differential effects in colon cancer progression [25]. Because *BRAF* and *KRAS* are oncogenes in the same pathway and yet are mutually exclusive in colon cancer [26], further analysis to dissect their function of transformation in the colonic epithelium may reveal marked functional differences about their oncogenic potential and tissue-specific pathway activation. Caco-2 cells are derived from a typical colon adenocarcinoma and are often used in the study of enterocyte differentiation because on reaching confluence, the cells

differentiate into a mature enterocyte phenotype, characterized by the formation of microvilli and brush borders [27]. Caco-2 cells harbor a truncating mutation in the *APC* gene [28], a Smad4 C-terminal missense mutations [29], and are further mutated at the p53 locus, generating a stop codon at amino acid 204, resulting in no detectable p53 expression [30]. Thus, these cells represent an ideal model system in which to study the transforming effects of *BRAF* and *KRAS* activating mutations in a transformation-permissive genetic background. Overexpression of these oncogenes in Caco-2 will also allow to study how the genetic background of a cell affects the outcome of an activating mutation and all that in comparison with commercially available human colon cancer cell lines carrying a more compromised mutated background, such as HT29^{V600E}, Colo205^{V600E}, DLD-1^{G13D}, and SW620^{G12V}. Briefly, we established stable Caco-2 cell lines constitutively expressing BRAF^{V600E} (Caco-BR13, -BR23) or KRAS^{G12V} (Caco-K6, -K15) and a control cell line stably transfected with the empty expression cassette (Caco-Neo). Clone selection was based on the protein expression levels for the two oncogenes, and their characterization was performed both *in vivo* and *in vitro*.

Materials and Methods

Stable Transfection and Characterization of Caco-2 Cells with BRAF^{V600E} and KRAS^{G12V}

The plasmids pH8-BRAF^{V600E}, kindly provided by Dr. Tsuneo Ikenoue (Department of Gastroenterology, Tokyo, Japan), and pcDNA3-KRAS^{G12V} [31] were transfected into Caco-2 cells using calcium phosphate. As a control, Caco-2 cells were also transfected with an empty pcDNA3 expression vector, and the arising clones were established by clonal selection with 0.5 mg/ml geneticin (Sigma-Aldrich, Poole, UK). Successful clones were further selected on the basis of protein expression for each oncogene. New BRAF^{V600E} and KRAS^{G12V} clones were named Caco-BR (or briefly BR) and Caco-K (or briefly K), respectively.

The growth rate of newly established clones was determined in replicate wells of a six-well dish seeded at 1×10^5 cells per well. Cells were harvested by trypsinization and counted using a Coulter counter (Model Z2; Coulter, Miami, FL) on days 1 to 5. For the anchorage-independent growth on soft agar, a layer of 0.5% agar in growth medium was first set in each well of a six-well dish. Growth medium containing 0.3% agar was mixed with 1×10^3 cells per well and overlaid onto the first layer of agar. Cells were allowed to form colonies in 5% CO₂ for 2 weeks at 37°C, fixed with methanol for 10 minutes at room temperature, and stained with 0.01% crystal violet. The colony formation was examined with a $\times 30$ objective of an inverted light microscope (Axiovert 25; Zeiss, Jena, Germany), and the total number of colonies in the top layer of agar was determined. To investigate the tumorigenicity of the clones, approximately 1×10^6 cells (Caco-2, Caco-NEO9, Caco-BR13, Caco-BR23, Caco-K6, Caco-K15, HT29, and DLD-1) in a total volume of 100 μ l of PBS were subcutaneously injected into each flank of a severe combined immunodeficient (SCID) mouse (Charles River Laboratories, Inc., L'Arbresle, Cedex, France) and monitored for tumor formation for a period of 5 months. All animal experiments were approved by the Animal Ethics Committee of the Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, and procedures were according to the guidelines approved by the United Kingdom Coordinating Committee of Cancer Research [32]. Tumors were isolated from each condition after 2 weeks of their appearance, and their weight was determined.

Protein Immunoblot Analysis

Whole cell lysates were prepared with lysis buffer containing protease and phosphatase inhibitors and were subjected to Western blot analysis. Methodology and antibody information is listed in Supplementary Materials and Methods.

Adherent Cell Proliferation Assay

Cells were plated into a 96-well plate at a density of 2×10^3 per well and left to grow for 24 hours. Cells were treated with two different concentrations of UO126 (30 and 60 μ M; ALX-270-237-M001; Alexis Biochemicals, Lausen, Switzerland) in triplicates. In each instance, cells were left to grow for 72 hours before being treated with 100 μ l of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (M2003; Sigma, St. Louis, MO) for 4 hours. MTT crystals were solubilized using isopropanol. The resulting absorbance was read in a Tecan Safire2 Microplate Reader (Tecan Austria GmbH, Grodig, Austria) at 560 nm. Absorbance readings were subtracted from the value of blank wells; the reduction in cell growth was calculated as a percentage of control absorbance in the absence of any inhibitor.

Senescence-Associated β -Galactosidase

Cells were washed twice with PBS, fixed with 2% formaldehyde and 0.2% glutaraldehyde prepared in PBS for 5 minutes, and washed twice with PBS. Cells were stained with X-Gal solution pH 6 (1 mg/ml X-Gal, 5 mM K₃Fe[CN]₆, 5 mM K₄Fe[CN]₆, 2 mM MgCl₂, 150 mM NaCl, 40 mM citric acid prepared in sodium phosphate buffer) prepared in PBS. Staining was performed at 37°C for approximately 16 hours without CO₂ [33]. Images were obtained using a Nikon Eclipse T-200 (Tokyo, Japan) inverted phase-contrast microscope equipped with an Olympus digital camera (Olympus, SP-510U2, Hamburg, Germany). The objective lens used was $\times 30$.

Immunofluorescence in Cultured Cells

Cells were grown on cover slips and fixed using 2% paraformaldehyde in PBS for 10 minutes at room temperature. Permeabilized cells were blocked with 4% FBS at room temperature for 1 hour and stained with anti-PML antibody (clone PGM3, SC-966; Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. Secondary antibody Alexa Fluor 488 goat anti-mouse (1:600, A11001; Molecular Probes, Eugene, OR) was applied to the cells for 1 hour at room temperature. The nuclei were stained with Hoechst No. 33342 (B2261; Sigma) for 10 minutes and coverslips were mounted on glass slides in Gelvatol/DABCO aqueous medium (Sigma-Aldrich). Samples were visualized with a Leica TCS SPE confocal laser scanning microscope,

and image acquisition was via the LAS AF software, both from Leica Lasertechnik, Heidelberg, Germany. The objective lens used was $\times 63$.

Flow Cytometric Analysis of Cell Cycle

For flow cytometry, 5×10^6 cells washed with PBS and fixed overnight with ice-cold 70% ethanol at -20°C . After fixation, cells were stained with 1 mg/ml propidium iodide in PBS solution containing 20 μ g/ml RNaseA and incubated at 37°C for 20 minutes. Samples were analyzed by flow cytometry (Calibur, Becton Dickinson, UK). To further study cell cycle checkpoints, cells were treated with growth medium containing 0.1 μ M nocodazole (M1404; Sigma), which is known to block cell cycle progression in G₂-M through disruption of mitotic spindles, for 2, 8 and 16 hours.

Gene Expression Reverse Transcription–Polymerase Chain Reaction Analysis

Total RNA (3 μ g) was reverse-transcribed into complementary DNA using the SuperScript II Reverse Transcriptase (Invitrogen, Karlsruhe, Germany) according to the manufacturer. Additional details are provided in Supplementary Materials and Methods.

Microsatellite Instability Analysis

Both Caco-BR cell lines, the parental cell line Caco-2 and microsatellite instability (MSI)–positive colon cancer cell lines DLD-1 and HCT116 were used to independently study MSI status by allelic profiling of mononucleotide repeat sequences (NR-21, NR-22, NR-24, BAT-25, and BAT-26) within the 3' and 5' untranslated regions of five different genes as previously described [34]. Briefly, one primer in each pair was labeled with one of the fluorescent markers 6-carboxyfluorescein (FAM), 6-carboxytetramethylrhodamine (TAMRA), or dichloro-2',7'-dimethoxy-6-carboxyfluorescein (JOE). Each mononucleotide repeat was amplified individually. Polymerase chain reaction (PCR) products were purified with Gene Clean Turbo PCR Kit (Bio101; QBiogene, Illkirch, Strasbourg, France) according to the manufacturer's instructions and were subsequently quantified on a 2% gel against molecular weight markers. Purified PCR products were directly gel-sequenced using an ABI PRISM 3100 genetic analyzer (MWG-Biotech; Ebersberg, Germany).

Results




Characterization of Caco-2 Clones Expressing Mutant BRAF^{V600E} (Caco-BR) and KRAS^{G12V} Oncogenes (Caco-K)

Plasmid (pH8-BRAF^{V600E} and pcDNA3-KRAS^{G12V}) concentrations were selected to provide an efficient protein expression of

Figure 1. BRAF^{V600E} significantly alters morphology and growth characteristics of Caco-2 cells. (A) Western blot analysis from selected Caco-2 clones stably transfected with KRAS^{G12V} (Caco-K6 and Caco-K15) and BRAF^{V600E} (Caco-BR13 and Caco-BR23) oncogenes. Left panel shows the expression levels of total KRAS and phosphorylation status of ERK1/2. Right panel shows the expression levels of total BRAF, active pBRAF, and phosphorylation status of ERK1/2. The vertical dividing black line indicates multiple fields taken from the same image. (B) Growth rate of Caco-2, Caco-NEO9, Caco-BR13, Caco-BR23, Caco-K6, and Caco-K15 cells. Results presented are average expression levels from at least three independent experiments. (C) Photographs illustrate the altered spindle-like morphology induced by BRAF^{V600E}. Representative images. Original magnification, $\times 30$. (D) BRAF^{V600E} efficiently transforms Caco-2 cells both *in vivo* and *in vitro*. Tumor formation efficiency of different Caco-BR and Caco-K cells and control colon cancer cells was assessed in SCID mice during a period of 5 months after cell injection. Tumor number represents successful tumor formed per group of cell line used. Tumor size (cm) and weight (g) describe the isolated tumors 2 weeks after their appearance per group of cell line used. For the SCID mice experiment, two or three 5-week-old female athymic mice were used per cell line. The values are mean \pm SD of three individual experiments performed in duplicates and triplicates. Accordingly, their ability to form colonies on 0.3% soft agar for 2 weeks was assessed and is represented in the table under the colony number. For soft agar assays, data were accumulated from two independent experiments, each clone in triplicate. ND indicates not determined; NI, not included in the experiment.

BRAF^{V600E} and KRAS^{G12V}. Initially, 10 different clones were selected for each oncogene and empty vector and checked for presence of the plasmid (data not shown). Although we isolated clones expressing varying amounts of mutant protein (data not shown), we

avoided further analysis of clones that expressed very high or very low levels (lower compared to controls) of transgene. For further analysis Caco-K6 and -K15 [31], clones were selected in case of KRAS^{G12V} transformation, whereas Caco-BR13 and -BR23 were



D *In vivo* and *in vitro* properties of BRAF^{V600E} and KRAS^{G12V} induced transformation.

	Caco-2	Caco-NEO9	BRAF ^{V600E}		KRAS ^{G12V}		Colon cell lines	
			Caco-BR13	Caco-BR23	Caco-K6	Caco-K15	HT29	DLD-1
Tumour Formation (days)	ND	ND	11.5±2.1	10±0.01	140±0.01	40±14	11.3±1.5	24±0.03
Number of Formed Tumours	-	-	14/14	14/14	2/10	3/10	16/16	4/4
Tumour size (cm)	-	-	1.17±0.32	1.31±0.50	0.28±0.04	0.8±0.02	1.37±0.40	1.27±0.77
Tumour mass (g)	-	-	0.38±0.20	0.36±0.21	0.23±0.19	0.3±0.03	0.51±0.50	1.70±0.24
Colony number	-	8.00±3.6	64.1±21.36	148.6±20.8	15.58±0.76	14.25±8.29	97.6±25	NI

the selected clones that expressed relatively low levels of highly phosphorylated BRAF^{V600E} (Figure 1A). In both cases of transformation, the level of oncoprotein was of similar expression compared with the control. To examine how the two mutations related to the downstream activities of signaling components known to be regulated by the RAS-RAF-MAPK pathway, we examined the phosphorylation status of ERK1/2 where both oncogenes managed to induce significant activation of this kinase (Figure 1A).

BRAF^{V600E} Alters Cell Growth and Cellular Morphology and Mediates Cell Transformation More Efficiently than KRAS^{G12V}

We noted that Caco-BR13 and -BR23 cell lines grew with different kinetics to Caco-K6 and -K15 and control cell lines (Caco-2 and NEO9) exhibiting a high proliferation rate and significantly quicker doubling times (Figure 1B). Caco-2 and NEO9 cell lines grew with similar kinetics. Photographs of Caco-2, NEO9, Caco-BR, and Caco-K cells illustrate the altered morphology specifically induced by the BRAF^{V600E} transformation (Figure 1C). Caco-BR cells seem to have adopted a spindle-shaped morphology and stopped forming large islets compared with Caco-2. However, even the Caco-2 clones expressing the highest levels of KRAS^{G12V} did not adopt this altered morphology, as previously shown [31]. In comparison, Caco-K cells formed tight contacts evidenced by their preference to grow in colonies with distinct boundaries between each cell (Figure 1C). In summary, our results demonstrate that the establishment of an altered more transformed morphology was restricted to expression of the mutant BRAF.

The tumor-inducing potential of each oncogene *in vivo* was examined in SCID mice, in which Caco-BR13 and -BR23 allowed the formation of significantly larger tumors than Caco-K6 and -K15 in significantly less time, whereas tumor formation of Caco-K cells varied from 1 to 5 months in some animals (Figure 1D). Moreover, both oncogenes (BRAF^{V600E} and KRAS^{G12V}) significantly increased the ability of Caco-2 cells to grow in soft agar (Figure 1D). Similarly, Caco-BR cells consistently formed colonies more efficiently than Caco-K cells and generated the same number of colonies on average with HT-29 cancer cell line (Figure 1D). BRAF^{V600E} confers higher transforming activity to Caco-2 cells compared with KRAS^{G12V} both *in vivo* and *in vitro*.

BRAF^{V600E} and KRAS^{G12V} Downstream Signaling

Analysis of the RAS-RAF-MEK-ERK pathway showed more efficient downstream ERK phosphorylation in the presence of KRAS^{G12V} rather than BRAF^{V600E}. Nevertheless significant was the activation of ERK2 (lower pERK1/2 band) in Caco-BR cells. In contrast, upstream ERK1/2 activator MEK was more activated in the Caco-BR cells, suggesting that other factors may be implicated in BRAF^{V600E} signaling, considering that the family member Raf-1 (CRAF) was found to be equally expressed and activated as BRAF in Caco-BR cells (Figure 2, A and B). To elucidate differential ERK activity, molecules that regulate its activation were analyzed. It was found that in Caco-BR cells (and not in Caco-K cells), kinase suppressor of RAS (KSR), a positive regulator of ERK activation, was significantly downregulated (Figure 2B). However, no significant change was observed in the RAF-1 kinase inhibitory protein (*RKIP*) gene suggesting no involvement (Figure W1). Therefore, limited KSR availabil-

ity in the BRAF^{V600E} system may be responsible for the moderate ERK activation regardless of increased BRAF-MEK activity.

Analysis of other RAS effector pathways showed that the survival pathway PI3K (pAKT) was significantly activated in the Caco-K cells, whereas the Jun N-terminal kinase (JNK) pathway was found to be downregulated in the Caco-BR cells (Figure 2C). Finally, the Ral pathway (RalA-GTP) remained unaffected in either case of oncogenic transformation (Figure W2).

Comparison of the RAS-RAF-MAPK signaling pathway in HT29 and Colo205 cells (V600E) *versus* DLD-1 and SW620 cells (G13D and G12V, respectively) revealed that, although pBRAF was higher in KRAS mutant cells, the pathway was more active in the BRAF mutant cell lines (Figure 2D).

Pharmacologic Inhibition of MAPK Signaling Pathway

To further explore ERK signaling, we analyzed its localization by immunostaining and discovered that, in Caco-BR cells, pERK was mainly localized in the nucleus compared with Caco-K and control cells, where it was found in the cytoplasm (Figure 3A). Pharmacological inhibition of the biochemical activities caused by mutant BRAF and KRAS was achieved using the specific MEK inhibitor UO126 in the presence of which cell growth of both Caco-BR and Caco-K cells was significantly reduced by approximately 50% to 60%, respectively, as shown by the MTT assay (Figure 3B). Under adherent culture conditions, the MEK inhibitor UO126 blocked growth through down-regulation of pERK within 1 hour and determined that cyclin D1 is the transcriptional target of KRAS^{G12V}. However, UO126 seemed insufficient in blocking cyclin D1 in Caco-BR cells in which pERK seemed to have a dynamic response to the treatment and recovers rapidly (Figure 3C).

Differential Expression of Senescence Markers by Oncogenic KRAS^{G12V}

Overexpression of KRAS^{G12V} but not BRAF^{V600E} in Caco-2 cells led to the acquisition of premature senescence-related markers as determined by SA- β -Gal staining (Figure 4A) and increased promyelocytic leukemia (PML) gene product localization, which has been previously associated with cellular senescence in RAS-arrested cells, and can provide further evidence of senescence activity [35] (Figure 4B). Regardless of senescence appearance, the cells did not arrest but continued proliferating and even increased their growth rate compared with Caco-2 cells (Figure 1B). Pigmentation that appears in the Caco-2 and NEO9 control cells after SA- β -Gal staining is considered as background staining because it is not comparable to the positive control staining (human embryonic lung fibroblasts HFL1 at PD55; Figure 4A). To determine whether oncogene-induced senescence in Caco-2 cells is mediated by the MAPK signaling pathway, pharmacological inhibition of ERK1/2 using UO126 was performed. Blocking of the MAPK pathway for 48 hours in Caco-K cells resulted in regression of the senescence-activated β -gal activity (Figure 4C).

In a parallel experiment, cell growth on growth factor depletion was analyzed for 3 to 5 days after which significant cell death was observed microscopically in Caco-K cells when Caco-BR cells and control cells continued proliferating normally (Figure 4D). This is of interest, considering that Caco-2 cells after KRAS^{G12V} transformation acquired senescence markers and at the same time growth factor-dependent




Figure 2. The MAPK pathway is activated in the Caco-BR and Caco-K cells. (A) Expression analysis of KRAS/RAF and biochemical detection of activated RAF proteins. (B) Signaling downstream of KRAS^{G12V} and BRAF^{V600E} and mRNA levels of KSR-positive regulator of pERK. (C) RAS effector pathways (PI3K and JNK) differentially regulated by KRAS^{G12V} and BRAF^{V600E}, respectively. (D) Biochemical detection of activated BRAF and its downstream effector ERK in control cell lines. Results presented are average expression levels among three independent experiments. Verticals dividing black lines indicate multiple fields taken from the same image.




Figure 3. ERK localization and the pharmacological inhibition of MAPK pathway. (A) Nuclear localization of pERK in Caco-BR cells. Representative confocal immunofluorescence images, double labeled with Hoechst (blue) and pERK (green). Original magnification, $\times 63$. (B) Pharmacological inhibition of cell proliferation using the MEK inhibitor UO126 at 30 and 60 μM for 72 hours and analyzed by MTT assay in Caco-BR and Caco-K cells. The inhibitor was replaced every 24 hours, and data in triplicates were normalized to the negative controls. (C) Determination of the inhibitory effect of 60 μM UO126 on pERK and cyclin D1 for various time points at the protein levels. Results were consistent among three independent experiments.

viability. Hoechst staining of Caco-K cells grown in the absence of serum was used to show death by apoptosis (Figure 4E).

These experiments show a clear difference in cell senescence marker staining between Caco-K and Caco-BR cells, which probably dramatically affects differential viability of these cells under growth factor deprivation.

Rb Inactivation and *p19^{ARF}* Collaborate with *BRAF^{V600E}* in Oncogenic Transformation

D-type cyclins (D1 and D3; G₁-phase cyclins), which prepare chromosomes for replication and initiate Rb phosphorylation, were significantly overexpressed in the Caco-BR transformed cells (Figure 5A). Nevertheless, both cyclins A and E (S-phase cyclins) were also significantly overexpressed in Caco-BR cells. These proteins initiate S phase as soon as M phase is over, supporting DNA replication along with E2Fs, and inactivate the Rb protein by completing its phosphorylation. These results come to support the finding that the Rb is hyperphosphorylated and therefore inactivated in Caco-BR

and not in Caco-K cells (Figure 5B). Nonphosphorylated Rb protein in the Caco-K cells is consistent with the appearance of senescent characteristics in those cells as described earlier (Figure 5, A and B).

Activation of the RAS-RAF pathway is known to mediate some of its effects through the activation of p16^{Ink4A} and p19^{ARF} [36]. Because p16^{Ink4A} is hypermethylated in Caco-2 cells [37], analysis was performed for the alternative reading frame of the same locus, the p19^{ARF} transcript along with other cell cycle regulators at transcriptional level (Figure 5C). Two members of the Ink family (p19^{ARF} and p15^{Ink4C}) were upregulated only in Caco-K cells, whereas the p27^{Kip1} member of the Cip/Kip family was upregulated in both cases of oncogenic transformation. Interestingly, p21^{Cip1} and p19^{Ink4D} were upregulated in Caco-BR cells. The cell cycle inhibitor *p57^{Kip2}* was the only gene not altered between the two oncogenes but upregulated compared with Caco-2 parental cell line (Figure 5C). Control cell lines HT29 (bearing endogenous BRAF^{V600E}) and DLD-1 (bearing endogenous KRAS^{G13D}) were also analyzed. The analysis regarding cell cycle inhibitors was limited to reverse transcription-PCR




Figure 4. Induction of *KRAS*^{G12V} induces senescence-related markers in Caco-2 colon epithelial cells as determined by (A) SA-β-Gal (representative images; original magnification, ×30) and (B) PML bodies staining (representative confocal immunofluorescence images, double labeled with Hoechst (blue) and PML (green); original magnification, ×63). (C) Pharmacologic inhibition of ERK1/2 using 30 μM UO126 for 48 hours resulted in regression of the senescence-activated β-gal activity in Caco-K cells. The inhibitor was replaced every 24 hours. Representative images. Original magnification, ×30. (D) Cell growth on growth factor depletion. Significant cell death was observed microscopically in Caco-K cells after 5 days of serum starvation, whereas Caco-BR and control cells (Caco-2, HT29, DLD-1) continued proliferating normally. All cells were cultured in triplicates with 0% and 10% FBS in parallel for comparison, and medium was replaced every day. (E) Hoechst staining showed apoptotic characteristics in the Caco-K cells after serum starvation. Representative images. Original magnification, ×30.




Figure 4. (continued).

(RT-PCR) because of the poor quality results yielded by the available antibodies.

BRAF^{V600E} Induces MSI in Caco-2 Cells by Altering DNA Content and Cell Cycle Distribution

The ability of transfected oncogenes to modulate the cell cycle distribution of Caco-2 cells was measured by FACS analysis. BRAF^{V600E} oncogene caused major cell cycle alterations when compared with pa-

rental Caco-2 cells, whereas no alterations were incurred in the presence of activated KRAS. Of interest is the fact that, after BRAF^{V600E} transformation, a new population of cells was generated that seems to contain a hypodiploid number of chromosomes and therefore a lower amount of DNA content. This is depicted by a shift to the left, on the FL2 axis, of the corresponding G₁ phase in both Caco-BR clones (hypodiploid peak; Figure 6A). To exclude the possibility of this being an apoptotic cell population, cells were treated with nocodazole for various time points after which there was a time-dependent





Figure 5. Differentially expressed cell cycle regulators in Caco-BR and Caco-K cells. (A) Protein analysis of cyclins A, B1, D1, D3, and E1 as well as (B) phosphorylation status of the Rb protein in KRAS^{G12V} versus BRAF^{V600E} clones and control cancer cells (HT29 and DLD-1). (C) Transcription analysis by RT-PCR of cell cycle inhibitors. Results were consistent among three independent experiments. Horizontal dividing black lines indicate group of images acquired with exact same conditions on a separate experiment. Vertical dividing black lines indicate multiple fields taken from the same image.






Figure 6. *BRAF*^{V600E} induce MSI in Caco-2-transformed cells. (A) FACS analysis of cell populations after propidium iodide staining reveals altered cell cycle distribution in BR- cells. *M1* indicates sub-G₁ phase; *M2*, G₁ phase; *M3*, S phase; *M4*, G₂/M phase. (B) Cells challenged with 0.1 μ M nocodazole to establish a time dependent reduction in the hypodiploid peak with a gradual shift of the cell populations toward the right on the FL2 axis. Cell cycle progression toward the G₂/M phase was monitored at the indicated time points and progressive appearance of dead cells at 8 and 16 hours and excluded the presence of apoptosis, which only appears after the 16-hour treatment point. Results were consistent among three independent experiments. (C) Relative RNA levels of DNA repair genes in Caco-BR and Caco-K cells and control HT29 and DLD-1 human colon cancer cell lines were evaluated by RT-PCR analysis. The analysis was performed in triplicates and the mean \pm SD is shown. DNA repair genes downregulated as a result of *BRAF*^{V600E}-induced transformation in Caco-2 cells. Columns indicate relative RNA level normalized to glyceraldehyde 3-phosphate dehydrogenase. (D) Electropherogram of the mononucleotide repeat markers NR-21, NR-22, NR-24, BAT-25, and BAT-26 of *BRAF*^{V600E}-transformed cells, their parental cell line Caco-2, and MSI-positive cell lines DLD-1 and HCT116. The appearance of numerous mononucleotide repeats of lower molecular weight in BR- cells in more than two MSI markers indicates MSI-H. Dashed line indicates the reference point relative to Caco-2 cells.

reduction in the hypodiploid peak with a gradual shift of the cell populations toward the right on the FL2 axis (Figure 6B). Cell population movement of the hypodiploid peak suggests ongoing cell cycle and is confirmed by statistical analysis of the percent of gated cells at each time point (data not shown). It is worth mentioning that during the 2-hour treatment with nocodazole, Caco-BR dividing cells colocalized with the G₁-phase peak of Caco-2-untreated cells. This observation could further support the lower DNA content in these cells. Therefore, the novel finding presented here suggests that BRAF^{V600E} oncogene may induce MSI characteristics to Caco-2 cells (Figure 6A).

Regarding the hypothesis of BRAF^{V600E}-induced MSI, specific DNA repair (MSH2 and Ku70) as well as nucleotide excision repair (NER) genes (*ERCC1-variant 1*, *ERCC3*, and *XPC*), found to be significantly downregulated in a microarray analysis (Joyce et al., unpublished observations) in Caco-BR cells, were validated by RT-PCR analysis to further support this hypothesis (Figure 6C).

The distinct role of BRAF^{V600E} with respect to mediating MSI was further supported by the allelic profiling of NR-21, NR-22, and NR-24 in which Caco-BR cells presented lower molecular weight fragments, visible as peaks that had shifted to left and varied in 4 bp or greater (Table W2) compared with the parental cell line Caco-2. When comparing Caco-BR cells to MSI-positive cell lines DLD-1 and HCT116 [6,38]; the electrophoretic pattern was only comparable with that observed in NR-22. In case of NR-21 and NR-42 loci, DLD-1 cells were represented by two distinct cell populations, one has been represented by normal-sized alleles and the other by peaks shifted to left, whereas the HCT116 were only represented by the lower molecular weight fragments. Both situations refer to MSI (Figure 6D). In contrast, the shift observed in BAT-25 and BAT-26 loci was below the cutoff level (≥ 4 bp) for Caco-BR23 but not Caco-BR13 and was considered to represent a polymorphism or somatic alteration. As previously, HCT116 were once again represented by a new cell population of lower molecular weight in BAT-26 locus, whereas a shift to the left (≥ 4 bp) was observed in BAT-25. Similarly, DLD-1 cells showed evidence of MSI in both BAT-25 and BAT-26 loci that were represented by shifts to the left (≥ 4 bp; Figure 6D).

Discussion

Differential Human Colon Cell Transformation by Oncogenic BRAF and KRAS

Several studies have investigated the role of BRAF^{V600E} and KRAS^{G12V} acting as oncogenes, but no study so far has compared these two activating mutations for their relevant transforming capabilities in colon cancer cells. Although it has been reported that BRAF^{V600E} is oncogenic when transfected into melanocytes [12], others have shown that BRAF^{V600E} transforms NIH3T3 immortal fibroblasts less efficiently than HRAS^{G12V} [11] and that its expression confers rat thyroid cells with little growth advantage because of concomitant activation of DNA synthesis and apoptosis [39]. Results obtained in the present study point toward the presence of a potent machinery carrying out aggressive transformation in the Caco-2 cells transfected with the BRAF^{V600E} oncogene.

BRAF^{V600E} and KRAS^{G12V} Signal Through ERK1/2 to Transform Caco-2 Colon Cells

Although KRAS^{G12V} could activate ERK more efficiently, it was BRAF^{V600E} that mediated complete transformation of colon epithe-

lial cells. However, although MEK activation in Caco-BR cells was more potent, it did not lead to significantly increased ERK signaling as previously described for BRAF^{V600E} [40]. In a similar study where BRAF^{V600E} was compared to HRAS^{G12V}, pERK levels were comparable to basal in the case of BRAF^{V600E} [41]. Furthermore, it was observed that, in Caco-BR cells, there was a marked difference between the two ERK isoforms, namely, ERK1 and ERK2, with the latter being far more activated. The important role of ERK2 in tumor growth has been recently revealed through RNAi-mediated knockdown, where ERK2 but not ERK1 inhibited growth of liver cancer cells *in vitro* and *in vivo* and silencing of ERK2 in NIH3T3 cells slowed down cell proliferation [42,43]. Taking into account that Caco-BR cells have enhanced cell growth, this selective ERK2 activation may play a crucial role in the regulation of cell proliferation in the BRAF^{V600E}-transformed cells regardless of moderate ERK activity. In addition, localization of pERK in the nucleus explains why moderate ERK activity is sufficient for the cell transformation of Caco-BR cells because activated ERK is translocated to the nucleus where it can phosphorylate and activate several molecules, such as cyclin D1, which is significantly activated and hyperphosphorylated in these cells. Increased kinase activation was also recorded for CRAF, coexpression of which can induce a B/C RAF complex in a RAS-dependent manner, inducing distinct biochemical properties [44]. A different explanation for the moderate but efficient ERK activation may lay with the fact that excessive amount of ERK signaling can lead to cell cycle arrest or senescence, and cells have been shown to switch from BRAF to CRAF signaling to avoid this [45]. Pharmacologic inhibition of the MAPK signaling pathway with respect to the hyperproliferative phenotype of Caco BR cells, and to a lesser extent, of Caco K cells was indicative that MAPK pathway is mediating cell transformation. ERK inhibition was more potent in case of KRAS^{G12V} cell transformation and had a profound effect on the transcriptional target cyclin D1.

Other RAS effector pathways such as the JNK and the PI3K were found differentially regulated between the two oncogenes, and no modulation was detected for Ral. These observations indicate that the expression of these oncoproteins induces abundant as well as variable downstream signaling in the colonic epithelium.

Also of interest is the significant activation of BRAF kinase in both DLD-1 and SW620 colon cancer cells, as a result of the upstream KRAS mutation present in these colon adenocarcinomas [46], which, however, does not induce pERK. However, the presence of BRAF^{V600E} in HT29 and Colo205 cells induces low pBRAF and high pERK. It is worth noting that the genetic background of these cell lines, apart from a KRAS or BRAF mutation, includes several other (p53, APC, PI3K, SMAD4). Here, we show the differential properties of two frequently mutated oncogenes in a permissive genetic background (in Caco-2 cell line) and how much these properties vary in the context of other mutations (e.g., HT29 and DLD-1 cell lines). This finding may have *in vivo* implications for personalized therapeutics in the future, considering how these mutations may influence pathway cross talk.

Attenuation of ERK Activation Due to KSR Down-regulation by BRAF^{V600E}

Nevertheless, the RAS-RAF-MAPK signaling pathway is not a simple one because many molecules have been identified to regulate its function. For example, signal flow from RAF to MEK is believed to be regulated by scaffold proteins such as KSR and protein interaction disrupters such as RKIP [47]. KSR is a putative scaffolding

protein for the RAF-MEK-ERK module that positively regulates ERK activation by binding to MEK and ERK constitutively [48]. In the present study, KSR was found significantly downregulated in the Caco-BR cells, and this could account for the moderate levels of ERK activation detected. Studies that associate KSR with cancer progression led to assume that pharmacological inactivation of KSR may serve as a treatment for RAS-driven malignancies, such as pancreatic cancer [49].

Presence of Rb and p19^{ARF} Overexpression Is Not Sufficient for RAS^{G12V}-Induced Transformation

We report here that colon epithelial cells transformed by BRAF^{V600E} presented no sign of senescence, whereas premature senescence was detected in the Caco-K cells, which also had ongoing cell cycle. To identify the exact mechanism by which KRAS^{G12V} switches from promoting proliferation to inducing senescence mechanism, the MAPK pathway was pharmacologically blocked, and replicative senescence was successfully prevented. Therefore, hyperactivation of the ERK pathway in Caco-K cells seems to lead to the opposite situation, which are the induction of a senescence program, growth factor-dependent cell viability, and finally not efficient cell transformation, which are not observed in Caco-BR cells.

Because in the parental Caco-2 cells the p53 is mutated and the p16^{Ink4} tumor suppressor is hypermethylated, the remaining possible mediator of senescence in the KRAS^{G12V} is the Rb pathway. Studies have shown that overexpression of RAS^{G12V} or Raf1 by retroviral delivery in normal human fibroblasts disrupted the Rb pathway [21,50]. In the present study, although the Rb was found to be selectively hyperphosphorylated and therefore deactivated in the Caco-BR cells, it was still functional in the Caco-K cells in which the p19^{ARF} was also significantly overexpressed. Together, these data show that both the Rb and the p19^{ARF} are working to induce senescence-related markers in Caco-K cells, which, however, escape from growth arrest. Cell survival could also be facilitated by the selective activation of AKT observed in the Caco-K cells. RAS-induced senescence has not been fully eluci-

dated and is considered to be the coordinated output of cell type-specific signaling networks [51]. This is further supported by the fact that additional growth factor extrinsically regulated signaling pathways are important for the viability of Caco-2 cells, whereas Caco-BR cell viability is not dependent on extrinsic growth factors. Increased proliferation of Caco-BR cells could be well explained by the increased expression of most cyclins including cyclin D1, D3, A, and E. Significantly increased expression of D cyclins could also account for the increased p21^{Cip1} because it has been shown that cyclin D1 specifically inhibits its degradation [19]. Both oncogenes (BRAF^{V600E} and KRAS^{G12V}) increase cyclin D1, which, when combined with Cdk4 and Cdk6, phosphorylates and inactivates Rb; however, this is not the case for the Caco-K cells. Accumulated p27^{Kip1} manages to take advantage of the hypophosphorylated Rb in the Caco-K cells and silences cyclin D/Cdk2 complex that may be present in the early G₁ phase. Working along this hypothesis, KRAS^{G12V} signaling is efficient in inducing cyclin B1, the most powerful mediator of cell cycle. Cyclin B1 is the cyclin localized in the cytoplasm, and its activation may be a direct signaling from increased cytoplasmic ERK in Caco-K cells.

BRAF^{V600E}-Mediated MSI in Caco-2 Cells

Cell cycle distribution of Caco-2 cells was notably affected after BRAF^{V600E} transformation because it was represented by a general shift to the left of the FL2 axis. This was indicative of a cell population with a lower DNA content due to a hypodiploid number of chromosomes. Nocodazole treatment of cells revealed that these cells were normally proliferating because they progressed through the M and G₂ phases. However, their dividing capacity was diminished, characteristic of cells containing a hypodiploid number of chromosomes. In a recent study, BRAF^{V600E} overexpression in a rat thyroid cell (PCCL3) among others managed to induce chromosomal instability (CIN) [39]. Caco-2 cells that are characterized by CIN acquire MSI characteristics in the presence of BRAF^{V600E}, a hypothesis also supported by a microarray analysis in the Caco-BR cells (Joyce et al., unpublished observations). The microarray study revealed




Figure 7. Differential effects of KRAS^{G12V} and BRAF^{V600E} on cell cycle. BRAF^{V600E} drives cells to high proliferation rate through nuclear pERK and the consequent phosphorylation of cyclin D1 (A), whereas KRAS^{G12V} generates senescence-related characteristics mediated by high cytoplasmic levels of pERK (B).

down-regulation of essential DNA repair (MSH2 and Ku70) and NER genes (*ERCC1-variant 1*, *ERCC3*, and *XPC*). Validation of array results confirmed down-regulation of *ERCC1*, *ERCC3*, and *XPC* in Caco-BR cells, all members of the NER subfamily. Deregulation in one of these NER members may result to failure of DNA repair initiation and cause defects in the mismatch repair mechanisms and its gene members [52]. Notably, DLD-1, already described to have MSI, also presents a significant down-regulation of *ERCC1-variant 1* gene, and their FACS profile is comparable to that of Caco-BR cells'. *BRAF* mutations have long been connected with MSI sporadic colorectal tumors because mismatch repair-deficient tumors have a very high incidence of *BRAF* mutations, and its overexpression in a rat cell line of thyroid origin (PCCL3) induced CIN [39,53–55]. The role of BRAF^{V600E} in MSI is further elucidated through the allelic profiling of certain mononucleotide repeats widely used to determine the microsatellite status. In particular, more than two of five analyzed loci (NR-21, NR-22, NR-24, BAT-25, and BAT-26) show instability in the Caco-BR cells, and therefore, we classify them as MSI-high (MSI-H) [56]. Because MSI cell lines display higher sensitivity to chemotherapeutics (CPT-11) than MSS cells, this could be later exploited to tailor chemotherapy based on MSI status [57,58].

We propose that the effect of BRAF^{V600E}, elicited on mitotic impairment, triggers chromosome breakage in the presence of a defective DNA damage response mechanism. As a result, cells continue cycling and acquire, within a single cell cycle, both chromosome rearrangements and abnormal chromosome numbers that remarkably mimic the complex genetic hallmark of tumorigenesis [59].

Conclusions

Our study demonstrates that BRAF^{V600E} is a more potent oncogene than KRAS^{G12V} in transforming colon epithelial cells, whereas KRAS^{G12V} managed to confer premature senescence to the same cell system. It was established that BRAF^{V600E} transformation was facilitated by the moderate activation of pERK, as a consequence of low KSR levels, which, however, translocated to the nucleus driving the increased proliferation rate in these cells through the hyperphosphorylation of cyclin D1 (Figure 7A). Conversely, the same MAPK pathway, only being more activated, was the mediator of KRAS^{G12V} oncogene-induced senescence markers and growth factor-dependent viability (Figure 7B). Within the different biochemical properties of these two oncogenes lays also the induction of MSI by BRAF^{V600E} rendering Caco-2 MSI-H.

References

- Bos JL (1989). *Ras* oncogenes in human cancer: a review. *Cancer Res* **49**, 4682–4689.
- Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J, Leggett BA, et al. (2004). Colorectal cancer with mutation in *BRAF*, *KRAS*, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. *J Clin Oncol* **22**, 4584–4594.
- Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, and Soderkvist P (2004). Mutation analysis of the *BRAF*, *ARAF* and *RAF-1* genes in human colorectal adenocarcinomas. *Carcinogenesis* **25**, 527–533.
- Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, et al. (2002). *BRAF* and *RAS* mutations in human lung cancer and melanoma. *Cancer Res* **62**, 6997–7000.
- Malumbres M and Barbacid M (2003). *RAS* oncogenes: the first 30 years. *Nat Rev Cancer* **3**, 459–465.
- COSMIC Database. Available at: <http://www.sanger.ac.uk/>. Accessed May 11, 2009.
- Al-Mulla F, Milner-White EJ, Going JJ, and Birnie GD (1999). Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. *J Pathol* **187**, 433–438.
- Andreyev HJ, Norman AR, Cunningham D, Oates JR, and Clarke PA (1998). Kirsten *ras* mutations in patients with colorectal cancer: the multicenter “RASCAL” study. *J Natl Cancer Inst* **90**, 675–684.
- Winder T, Mundlein A, Rhomberg S, Dirschmid K, Hartmann BL, Knauer M, Drexel H, Wenzl E, De Vries A, and Lang A (2009). Different types of *K-Ras* mutations are conversely associated with overall survival in patients with colorectal cancer. *Oncol Rep* **21**, 1283–1287.
- Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, et al. (2003). Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. *Cancer Res* **63**, 8132–8137.
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002). Mutations of the *BRAF* gene in human cancer. *Nature* **417**, 949–954.
- Wellbrock C, Karasarides M, and Marais R (2004). The RAF proteins take centre stage. *Nat Rev Mol Cell Biol* **5**, 875–885.
- Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, et al. (2004). Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. *J Clin Oncol* **22**, 3950–3957.
- Genot E, Reif K, Beach S, Kramer I, and Cantrell D (1998). p21^{ras} initiates Rac-1 but not phosphatidylinositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes. *Oncogene* **17**, 1731–1738.
- Woods D, Parry D, Cherwinski H, Bosch E, Lees E, and McMahon M (1997). Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21^{Cip1}. *Mol Cell Biol* **17**, 5598–5611.
- Kasid U and Dritschilo A (2003). RAF antisense oligonucleotide as a tumor radiosensitizer. *Oncogene* **22**, 5876–5884.
- Alao JP (2007). The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic intervention. *Mol Cancer* **6**, 24.
- Mermelshtein A, Gerson A, Walfisch S, Delgado B, Shechter-Maor G, Delgado J, Fich A, and Gheber L (2005). Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. *Br J Cancer* **93**, 338–345.
- Coleman ML, Marshall CJ, and Olson MF (2003). Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. *EMBO J* **22**, 2036–2046.
- Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, Harter ML, Dillehay LE, Claudio PP, Giordano A, et al. (1998). Activated Raf-1 causes growth arrest in human small cell lung cancer cells. *J Clin Invest* **101**, 153–159.
- Zhu J, Woods D, McMahon M, and Bishop JM (1998). Senescence of human fibroblasts induced by oncogenic Raf. *Genes Dev* **12**, 2997–3007.
- Janderova-Rossmeslova L, Novakova Z, Vlasakova J, Philimonenko V, Hozak P, and Hodny Z (2007). PML protein association with specific nucleolar structures differs in normal, tumor and senescent human cells. *J Struct Biol* **159**, 56–70.
- Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, and Peepers DS (2005). BRAF^{V600E}-associated senescence-like cell cycle arrest of human naevi. *Nature* **436**, 720–724.
- Serrano M, Lin AW, McCurrach ME, Beach D, and Lowe SW (1997). Oncogenic *ras* provokes premature cell senescence associated with accumulation of p53 and p16^{INK4a}. *Cell* **88**, 593–602.
- Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, et al. (2008). Differential effects of oncogenic *K-Ras* and *N-Ras* on proliferation, differentiation and tumor progression in the colon. *Nat Genet* **40**, 600–608.
- Garnett MJ and Marais R (2004). Guilty as charged: *B-RAF* is a human oncogene. *Cancer Cell* **6**, 313–319.
- Zweibaum A, Triadou N, Kedinger M, Augeron C, Robine-Leon S, Pinto M, Rousset M, and Haffen K (1983). Sucrase-isomaltase: a marker of foetal and malignant epithelial cells of the human colon. *Int J Cancer* **32**, 407–412.
- Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, and Bodmer WF (1997). β -Catenin mutations in cell lines established from human colorectal cancers. *Proc Natl Acad Sci USA* **94**, 10330–10334.
- De Bosscher K, Hill CS, and Nicolas FJ (2004). Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. *Biochem J* **379**, 209–216.
- Djelloul S, Forgue-Lafitte ME, Hermelin B, Mareel M, Bruyneel E, Baldi A, Giordano A, Chastre E, and Gespach C (1997). Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells. Status of the pRb1 and pRb2 tumor suppressor gene products. *FEBS Lett* **406**, 234–242.

- [31] Roberts ML, Drosopoulos KG, Vasileiou I, Stricker M, Taoufik E, Maercker C, Guialis A, Alexis MN, and Pintzas A (2006). Microarray analysis of the differential transformation mediated by Kirsten and Harvey *Ras* oncogenes in a human colorectal adenocarcinoma cell line. *Int J Cancer* **118**, 616–627.
- [32] Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, et al. (1998). United Kingdom Co-ordinating Committee on Cancer Research (UKCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). *Br J Cancer* **77**, 1–10.
- [33] Dimiri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, and Pereira-Smith O (1995). A biomarker that identifies senescent human cells in culture and in aging skin *in vivo*. *Proc Natl Acad Sci USA* **92**, 9363–9367.
- [34] Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, and Hamelin R (2002). Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. *Gastroenterology* **123**, 1804–1811.
- [35] Ferbeyre G (2007). Barriers to Ras transformation. *Nat Cell Biol* **9**, 483–485.
- [36] Ohtani N, Zebede Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharricks AD, Peters G, and Hara E (2001). Opposing effects of Ets and Id proteins on p16^{INK4a} expression during cellular senescence. *Nature* **409**, 1067–1070.
- [37] Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, and Baylin SB (1995). Inactivation of the *CDKN2/p16/MTS1* gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Res* **55**, 4525–4530.
- [38] Russo MT, Blasi MF, Chiera F, Fortini P, Degan P, Macpherson P, Furuichi M, Nakabeppu Y, Karran P, Aquilina G, et al. (2004). The oxidized deoxynucleoside triphosphate pool is a significant contributor to genetic instability in mismatch repair–deficient cells. *Mol Cell Biol* **24**, 465–474.
- [39] Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, and Fagin JA (2005). Conditional BRAF^{V600E} expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. *Cancer Res* **65**, 2465–2473.
- [40] Dhillon AS and Kolch W (2004). Oncogenic *B-Raf* mutations: crystal clear at last. *Cancer Cell* **5**, 303–304.
- [41] Benjamin CL and Ananthaswamy HN (2008). Oncogenic potential of *BRAF* versus *RAS*. *Cancer Lett* **261**, 137–146.
- [42] Bessard A, Fremin C, Ezan F, Fautrel A, Gailhouste L, and Baffet G (2008). RNAi-mediated ERK2 knockdown inhibits growth of tumor cells *in vitro* and *in vivo*. *Oncogene* **27**, 5315–5325.
- [43] Lefloch R, Pouyssegur J, and Lenormand P (2008). Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. *Mol Cell Biol* **28**, 511–527.
- [44] Garnett MJ, Rana S, Paterson H, Barford D, and Marais R (2005). Wild-type and mutant *B-RAF* activate *C-RAF* through distinct mechanisms involving heterodimerization. *Mol Cell* **20**, 963–969.
- [45] Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, Bastian BC, Springer C, and Marais R (2006). In melanoma, *RAS* mutations are accompanied by switching signaling from *BRAF* to *CRAF* and disrupted cyclic AMP signaling. *Cancer Res* **66**, 9483–9491.
- [46] Banerji U, Affolter A, Judson I, Marais R, and Workman P (2008). *BRAF* and *NRAS* mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. *Mol Cancer Ther* **7**, 737–739.
- [47] Kolch W (2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. *Biochem J* **351** (Pt 2), 289–305.
- [48] Razidlo GL, Kortum RL, Haferbier JL, and Lewis RE (2004). Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation. *J Biol Chem* **279**, 47808–47814.
- [49] Xing HR, Cordon-Cardo C, Deng X, Tong W, Campodonico L, Fuks Z, and Kolesnick R (2003). Pharmacologic inactivation of kinase suppressor of *ras-1* abrogates Ras-mediated pancreatic cancer. *Nat Med* **9**, 1266–1268.
- [50] Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, and Lowe SW (1998). Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. *Genes Dev* **12**, 3008–3019.
- [51] Courtois-Cox S, Genter Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, and Cichowski K (2006). A negative feedback signaling network underlies oncogene-induced senescence. *Cancer Cell* **10**, 459–472.
- [52] Wang G, Dombkowski A, Chuang L, and Xu XX (2004). The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response. *Cell Res* **14**, 303–314.
- [53] Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, and Velculescu VE (2002). Tumorigenesis: *RAF/RAS* oncogenes and mismatch-repair status. *Nature* **418**, 934.
- [54] Oliveira C, Velho S, Domingo E, Preto A, Hofstra RM, Hamelin R, Yamamoto H, Seruca R, and Schwartz S Jr (2005). Concomitant *RASSF1A* hypermethylation and *KRAS/BRAF* mutations occur preferentially in MSI sporadic colorectal cancer. *Oncogene* **24**, 7630–7634.
- [55] Vilar E, Scaltriti M, Balmana J, Saura C, Guzman M, Arribas J, Baselga J, and Taberero J (2008). Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. *Br J Cancer* **99**, 1607–1612.
- [56] Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, et al. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* **58**, 5248–5257.
- [57] Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, et al. (2009). Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. *J Clin Oncol* **27**, 1814–1821.
- [58] Des GG, Uzzan B, Nicolas P, Schischmanoff O, and Morere JF (2009). Microsatellite instability: a predictive marker in metastatic colorectal cancer? *Target Oncol* **4**, 57–62.
- [59] Dunican DS, McWilliam P, Tighe O, Parle-McDermott A, and Croke DT (2002). Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. *Oncogene* **21**, 3253–3257.
- [60] Marshall OJ (2004). PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. *Bioinformatics* **20** (15), 2471–2472.

Supplementary Materials and Methods

Protein Immunoblot Analysis and Glutathione S-Transferase Pull-down Assay

Whole cell lysates were prepared with lysis buffer containing 50 mM Tris-HCl (pH 7.4), 250 mM sucrose, 1 mM EDTA, 10 mM NaF, 1 mM EGTA, 1% (v/v) Triton X-100, 1 mM sodium orthovanadate, 10 µg/ml leupeptin, and 0.2 mM PMSF. Cells were lysed by swelling in hypotonic buffer (10 mM Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA). For Western blot analysis, protein concentrations were determined by the Bradford assay (Bio-Rad Laboratories, Hercules, CA) using bovine serum albumin as a standard. Extracts were resolved on SDS-PAGE (10% or 12% wt/vol acrylamide), transferred to nitrocellulose membrane (Whatman; Scheiche & Schuell, Dassel, Germany). Antibodies used were as follows: K-Ras (sc-30), B-Raf (sc-5284), cyclin D1 (sc-718), pTyr²⁰⁴ ERK (sc-7383), and α -tubulin (sc-8035) that were purchased from Santa Cruz; pSer⁴⁴⁵ B-Raf (2696), pSer⁴⁷³ Akt (9271), pSer^{217/221} MEK1/2 (9121), and pThr^{183/185} SAPK/JNK (9251) that were purchased from Cell Signaling (Danvers, MA); cyclin E (3512-1), cyclin A (3507-1), cyclin B1 (3508-1), and cyclin D3 (3571-1) that were purchased from Clontech (Heidelberg, Germany); C-Raf (610151), Rb (554136), and Ral A (610221) that

were purchased from BD (Franklin Lakes, NJ); and pSer³³⁸-Raf-1 (05-538; Upstate, Lake Placid, NY).

For the glutathione S-transferase (GST) pull-down assay, 200 µg of the identical protein extract used for Western analysis was incubated with GST-Ral binding protein for glutathione agarose beads for 1 hour by rotating at 4°C. Beads were washed four times in cell lysis buffer before being loaded on 12% wt/vol SDS-PAGE. The construct was kindly provided by Johannes L. Bos (Centre for Biomedical Genetics, Utrecht, the Netherlands). Fold expression of all proteins analyzed was determined after band intensity was established using Molecular Dynamics Image Quant Software (Amersham Biosciences, Uppsala, Sweden).

Gene Expression RT-PCR Analysis

For RT-PCR amplification, 2.5 µl of complementary DNA template, from all clones and control cells lines, was analyzed against different primers (20 pmol each) (Table W1) for a total of 25 µl of reaction. Each sample was amplified using the MJ thermocycler PTC-200 (Bio-Rad, Hercules, CA). Intensity values were measured using Molecular Dynamics Image Quant Software. All PCR products were normalized to GAPDH expression.




Figure W1. RT-PCR analysis of mRNA levels for RKIP, the negative regulator of pERK. Results were consistent among three independent experiments.




Figure W2. RAS effector pathway Ral expression analysis and activation by GST pull-down assay in Caco-K and Caco-BR cells. Results were consistent among three independent experiments.

Table W1. Primers Used for RT-PCR.

Primers	Sequence	°C (No. of Cycles)	Size (bp)	Reference
p19 ^{Arf}	F: 5'-CCCTCGTGCTGATGCTACTGA-3' R: 5'-ACCACCAGCGTGTCCAGGAA-3'	56 (35)	200	[60]
p15 ^{Ink4b}	F: 5'-AGGGATATTAGGAGTGTGTGAC-3' R: 5'-CCATCGGAAGATTTCGTAGCC-3'	60 (30)	114	[60]
p19 ^{Ink4d}	F: 5'-CAGTTTGTGGCTTATAGGTG-3' R: 5'-CCCTTCTCTGTCCAACAC-3'	56 (30)	101	[60]
p21 ^{Cip1/Waf1}	F: 5'-GGAAGACCATGTGGACCTGT-3' R: 5'-GGCGTTTGGAGTGGTAGAAA-3'	59 (32)	146	[60]
p27 ^{Kip1}	F: 5'-CCACGAAGAGTTAACCCGGG-3' R: 5'-GTCTGCTCCACAGAACCGGC-3'	60 (35)	450	[60]
p57 ^{Kip2}	F: 5'-CTGACCAGCTGCACTCGGGGATTC-3' R: 5'-GCCGCCGGTTGCTGTACATGA-3'	60 (35)	424	[60]
Cyclin D1	F: 5'-CTTCCTCTCCAAAATGCCAG-3' R: 5'-AGAGATGGAAGGGGAAAGA-3'	58 (28)	717	[60]
Cyclin D3	F: 5'-ACTGGATGCTGGAGGTATGT-3' R: 5'-GACAGGTAGCGATCCAGGTA-3'	57 (35)	85	[60]
Cyclin E1	F: 5'-TGCGCAAATAGAGAGGAAGTC-3' R: 5'-GCACCACTGATACCTGAA-3'	58 (28)	639	[60]
RKIP	F: 5'-TCATTTCTGGTGGTCAAC-3' R: 5'-CCTGTCTGCTCGTAAAC-3'	55 (28)	133	[60]
KSR	F: 5'-CCTTCCTGCCACTAACTC_3' R: 5'-GGGTGCTCCTTCTTTGTC-3'	56 (30)	210	[60]
Ku70	F: 5'-GATGCACCTGAAGAAACCTG-3' R: 5'-GATTCTCTCAAAGTGAAACCT-3'	58 (30)	101	[60]
XPC	F: 5'-CCCAGCCGCTTTACCA-3' R: 5'-TGCATTAAGTAAATGTTCCAATGA-3'	60 (28)	97	[60]
ERCC1-variant 1	F: 5'-TGACCACATTTGGATCTCTG-3' R: 5'-CAACTCCTTGGGTTCTTTCC-3'		114	[60]
ERCC3	F: 5'-TGCCATTTCTAAGACTGCTG-3' R: 5'-TTCATCCTTGTCCATTTGCT-3'	60 (28)	123	[60]
GAPDH	F: 5'-GAAGTGAAGGTCGGAGT-3' R: 5'-CATGGGTGGAATCATATTGGAA-3'	58 (28)	155	[60]

Table W2. Allelic Peaks (bp).

Cell Line	MSI Loci	Peak 1	Peak 2	Peak 3
Caco-BR13	BAT-25	118	119	
Caco-BR23	BAT-25	119	120	
Caco-2	BAT-25	122	123	
DLD-1	BAT-25	118	119	
HCT116	BAT-25	117	118	
Caco-BR13	BAT-26	107	108	
Caco-BR23	BAT-26	108	109	
Caco-2	BAT-26	111	112	
DLD-1	BAT-26	108	109	
HCT116	BAT-26	98	99	
Caco-BR13	NR-21	89	90	91
Caco-BR23	NR-21	90	91	92
Caco-2	NR-21	95	96	96
DLD-1	NR-21	89	90	91
HCT116	NR-21	88	89	90
Caco-BR13	NR-22	131	132	133
Caco-BR23	NR-22	131	132	133
Caco-2	NR-22	135	136	
DLD-1	NR-22	131	132	133
HCT116	NR-22	129	130	131
Caco-BR13	NR-24	119	120	121
Caco-BR23	NR-24	120	121	122
Caco-2	NR-24	124	125	126
DLD-1	NR-24	118	119	120
HCT116	NR-24	117	118	119